<DOC>
	<DOC>NCT00804401</DOC>
	<brief_summary>Compare the rate and extent of absorption of two oral formulations of Naproxen Tablets, administered as a 1 x 500 mg tablet under fasting conditions.</brief_summary>
	<brief_title>Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>healthy men or women, nonsmoker, 18 years of age or older willing to participate and sign a copy of the informed consent form clinically significant illnesses or surgery within 4 weeks prior to study dosing body mass index greater than or equal to 30.0 recent history of drug or alcohol addiction or abuse pregnant or lactating women history of allergic response to naproxen, NSAIDs, or other related drugs, or to heparin history of allergic reactions such as asthma, rhinitis, nasal polyps, urticaria, and hypotension associated with the use of aspirin or other NSAIDs history or known presence of gastrointestinal ulceration, bleeding and perforation use of tobacco products within 6 months prior to study dosing evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant receipt of any drugs as part of a research study within 30 days prior to study dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>bioequivalency</keyword>
	<keyword>Naproxen</keyword>
</DOC>